Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Abstract

BACKGROUNDA vaccine to interrupt the transmission of tuberculosis is needed. METHODSWe conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E tuberculosis vaccine in Kenya, South Africa, and Zambia.Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in a 1:1 ratio) to receive two doses of either M72/AS01 E or placebo intramuscularly 1 month apart.Most participants had previously received the bacille Calmette-Guérin vaccine.We assessed the safety of M72/AS01 E and its efficacy against progression to bacteriologically confirmed active pulmonary tuberculosis disease.Clinical suspicion of tuberculosis was confirmed with sputum by means of a polymerase-chain-reaction test, mycobacterial culture, or both. RESULTSWe report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial.A total of 1786 participants received M72/AS01 E and 1787 received placebo, and 1623 and 1660 participants in the respective groups were included in the according-to-protocol efficacy cohort.A total of 10 participants in the M72/AS01 E group met the primary case definition (bacteriologically confirmed active pulmonary tuberculosis, with confirmation before treatment), as compared with 22 participants in the placebo group (incidence, 0.3 cases vs. 0.6 cases per 100 person-years).The vaccine efficacy was 54.0% (90% confidence interval [CI], 13.9 to 75.4; 95% CI, 2.9 to 78.2; P = 0.04).Results for the total vaccinated efficacy cohort were similar (vaccine efficacy, 57.0%; 90% CI, 19.9 to 76.9; 95% CI, 9.7 to 79.5; P = 0.03).There were more unsolicited reports of adverse events in the M72/ AS01 E group (67.4%) than in the placebo group (45.4%) within 30 days after injection, with the difference attributed mainly to injection-site reactions and influenzalike symptoms.Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two groups. CONCLUSIONSM72/AS01 E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 35

1. 1.
   The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling · 2016

   No notice
2. 2.

   World Health Organization. Global Tuberculosis Report 2017. (http://www.who.int/tb/publications/global_report/en/)

   Not in our library

3. 3.

   Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017;Mar 5.

   Not in our library10.1016/s2213-2600(17)30079-6

4. 4.

   Harris RC, Sumner T, Knight GM, White RG. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Human vaccines & immunotherapeutics 2016;12:2813-32.

   Not in our library10.1080/21645515.2016.1205769

5. 5.

   Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2014;58:470-80.

   Not in our library10.1093/cid/cit790

6. 6.

   Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AS, Dalemans W, Skeiky YA. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 2004;138:139-44.

   Not in our library10.1111/j.1365-2249.2004.02609.x

7. 7.

   Skeiky YA, Lodes MJ, Guderian JA, et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 1999;67:3998-4007.

   Not in our library10.1128/iai.67.8.3998-4007.1999

8. 8.

   Dillon DC, Alderson MR, Day CH, et al. Molecular characterization and human Tcell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999;67:2941-50.

   Not in our library10.1128/iai.67.6.2941-2950.1999

9. 9.

   Day CL, Tameris M, Mansoor N, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013;188:492-502.

   Not in our library10.1164/rccm.201208-1385oc

10. 10.

    Gillard P, Yang PC, Danilovits M, et al. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study. Tuberculosis (Edinb) 2016;100:118-27.

    Not in our library10.1016/j.tube.2016.07.005

11. 11.

    Idoko OT, Owolabi OA, Owiafe PK, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb) 2014;94:564-78.

    Not in our library10.1016/j.tube.2014.07.001

12. 12.

    Kumarasamy N, Poongulali S, Bollaerts A, et al. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults. Medicine (Baltimore) 2016;95:e2459.

    Not in our library10.1097/md.0000000000002459

13. 13.

    Leroux-Roels I, Forgus S, De Boever F, et al. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013;31:2196-206.

    Not in our library10.1016/j.vaccine.2012.05.035

14. 14.

    Montoya J, Solon JA, Cunanan SR, et al. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 2013;33:1360-75.

    Not in our library10.1007/s10875-013-9949-3

15. 15.

    Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 2015;33:4025-34.

    Not in our library10.1016/j.vaccine.2015.05.088

16. 16.

    Thacher EG, Cavassini M, Audran R, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 2014;28:1769-81.

    Not in our library10.1097/qad.0000000000000343

17. 17.

    Williams A, Orme IM. Animal Models of Tuberculosis: An Overview. Microbiology spectrum 2016;4.

    Not in our library10.1128/microbiolspec.tbtb2-0004-2015

18. 18.

    Skeiky YA, Alderson MR, Ovendale PJ, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004;172:7618-28.

    Not in our library10.4049/jimmunol.172.12.7618

19. 19.

    Brandt L, Skeiky YA, Alderson MR, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004;72:6622-32.

    Not in our library10.1128/iai.72.11.6622-6632.2004

20. 20.

    Tsenova L, Harbacheuski R, Moreira AL, et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 2006;74:2392-401

    Not in our library10.1128/iai.74.4.2392-2401.2006

21. 21.

    Irwin SM, Izzo AA, Dow SW, et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 2005;73:5809-16.

    Not in our library10.1128/iai.73.9.5809-5816.2005

22. 22.

    Lewinsohn DA, Lines RA, Lewinsohn DM. Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis-specific CD8+ T cells. Am J Respir Crit Care Med 2002;166:843-8.

    Not in our library10.1164/rccm.2110094

23. 23.

    Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an adolescent cohort study in South Africa. PloS one 2011;6:e17984.

    Not in our library10.1371/journal.pone.0017984

24. 24.

    Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebocontrolled phase 2b trial. Lancet 2013;381:1021-8.

    Not in our library10.1016/s0140-6736(13)60177-4

25. 25.

    von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010;24:675-85.

    Not in our library10.1097/qad.0b013e3283350f1b

26. 26.

    Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies, Hope For Subunit Vaccines. AERAS. Available at http://www.aeras.org/pressreleases/results-from-innovative-phase-2-tuberculosis-vaccinetrial- offer-potential#.Wtg4Q3-ZGbo Accessed 19 April 2018.

    Not in our library

27. 27.

    Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nature reviews Immunology 2017;17:691-702.

    Not in our library10.1038/nri.2017.69

28. 28.

    Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999;353:444-9.

    Not in our library10.1016/s0140-6736(98)03406-0

29. 29.

    Barreto ML, Pereira SM, Pilger D, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCGREVAC cluster-randomised trial. Vaccine 2011;29:4875-7.

    Not in our library10.1016/j.vaccine.2011.05.023

30. 30.

    Andrews JR, Nemes E, Tameris M, et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. The Lancet Respiratory Medicine 2017;5:282-90.

    Not in our library10.1016/s2213-2600(17)30060-7

31. 31.

    Lau Eea. Prevalence of latent TB infection among adults in endemic regions screened for a phase IIb, double-blind, randomized, placebo-controlled study to evaluate GSK candidate vaccine M72/AS01E.. International AIDS Society - TB2016; 2016.

    Not in our library

32. 32.

    Mahomed H, Hawkridge T, Verver S, et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. The International Journal of Tuberculosis and Lung Disease 2011;15:331-6.

    Not in our library

33. 33.

    Mahomed H, Hughes EJ, Hawkridge T, et al. Comparison of Mantoux skin test with three generations of a whole blood IFN-γ assay for tuberculosis infection. The International Journal of Tuberculosis and Lung Disease 2006;10:310-6.

    Not in our library

34. 34.

    Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. The International Journal of Tuberculosis and Lung Disease 2010;14:406-12.

    Not in our library

35. 35.

    Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34.

    Not in our library10.1016/s0140-6736(02)09742-8

Cited by papers we hold 4

• Vaccine adjuvants: mechanisms and platforms · 2023
  No notice
• End-point definition and trial design to advance tuberculosis vaccine development · 2022
  Not checked
• Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells · 2020
  Not checked
• The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.